AbCellera Biologics(US:ABCL)2025-08-07 21:00Business Updates - The company has completed its transition into a clinical-stage biotech and is on track to complete key priorities[4] - Phase 1 clinical trials for ABCL635 (for vasomotor symptoms) were initiated in June 2025[4, 5, 6] - Phase 1 clinical trials for ABCL575 (immunology & inflammation) were initiated in July 2025[4, 7] - ABCL688, a development candidate for autoimmunity, has been nominated for CTA-enabling studies[4, 14] Financials - The company has approximately $750 million in available liquidity to execute its strategy[4, 17] - The company has approximately $580 million in total cash, cash equivalents, and marketable securities[18, 28] - The company has approximately $170 million in total available government funding[16] - Q2 2025 revenue was $39.2 million, a decrease of $1.7 million compared to $40.9 million in Q2 2024[23] - Q2 2025 net loss was $34.7 million, equivalent to ($0.12) per share[25, 26] - Q2 2025 Research and Development expenses were $19.0 million, a decrease of $1.2 million compared to $20.2 million in Q2 2024[23]